Company and Stock Identity

How Insilico Medicine Connects to the Public Market

Company structure
Public company
Market access
Direct listing: Hong Kong Stock Exchange: 03696.
Stock name
Insilico Medicine Cayman TopCo
Ticker and exchange
Hong Kong Stock Exchange: 03696
Research focus
Separate platform licensing, research partnerships, and internally developed drug programs, then date each program by discovery, preclinical, or clinical stage.

Insilico Medicine listed on the Hong Kong Stock Exchange on December 30, 2025. Older descriptions of the company as private predate that listing.

A current price is not available in the automated United States market snapshot. Use the named exchange or the company investor-relations page for current trading data.

Open the public company market data feed for the full directory, ownership relationships, stock identifiers, and dated snapshots.

First-Hand Company News

Latest Developments

... Insilico Medicine ... Company source

Insilico Medicine's 2.5 billion dollar SK deal starts with up to 18 million dollars

Insilico Medicine said on 29 June 2026 that it signed a research collaboration with SK Biopharmaceuticals to find AI-designed drug candidates for neuroimmune disorders of the central nervous system, covering neuroinflammatory, neurodegenerative and rare neurological conditions. The company states a total deal value exceeding 2.5 billion dollars in potential development, regulatory and commercial milestones, with up to 18 million dollars in upfront and near-term milestone payments and single-digit royalties on net sales. Insilico says it uses its Pharma.AI platform for discovery while SK Biopharmaceuticals handles late-stage development and commercialisation, and reports nominating 31 preclinical candidates since 2021 with 13 receiving investigational new drug approval, from a pipeline of more than 40 candidates.

Why it matters: Milestone-based deal values in this industry are almost always a ceiling that is never reached, because each payment depends on a molecule clearing a stage most molecules do not clear. The cash that matters now is up to 18 million dollars, and for a company listed on the Hong Kong exchange that is the figure a shareholder should model. The genuinely interesting number is the other one: 31 preclinical candidates since 2021 with 13 investigational new drug approvals is a real conversion rate, and it is the measure of whether the AI platform works. Neurological disease is also among the hardest places to prove a drug, so expect a long wait before any milestone triggers.

See company developments across the healthcare AI market.

Careers and Qualifications

What to Know Before Applying

Work areas: Computational biology, medicinal chemistry, machine learning, clinical development, software, and biopharma partnerships.

Qualification signal: Scientific roles commonly require advanced training in biology, chemistry, medicine, or computation. Evidence that you can connect a model to an experimental result matters more than a broad AI certificate.

Check current roles at Insilico Medicine. A careers page is the source of record for openings. This profile does not claim a role is open unless the company lists it now.

Related Healthcare AI Roles

Training to Compare

Buyer Snapshot

Best-fit buyer
Pharmaceutical R&D, biotechnology leadership, translational science, business development, and investors
Primary use case
Identify targets, design molecules, prioritize experiments, and connect biomedical data to research decisions
Typical deployment
Ranges from software and data partnerships to platform collaborations and internally owned drug pipelines

Evidence questions

  • Which results are prospective, reproduced, and tied to a clinical or experimental endpoint?
  • How many programs are AI-originated, AI-assisted, partnered, or internally owned?
  • What has advanced beyond target identification and preclinical reporting?

Regulatory and workflow questions

  • Which entity owns development, validation, and regulatory responsibility for each program?
  • How are model-generated hypotheses reviewed before experimental or clinical use?
  • What claims are about research productivity versus a regulated product?

Data and contract questions

  • Who owns generated molecules, targets, models, and derived data?
  • Which proprietary datasets create defensibility and which are licensed?
  • Can a partner reproduce outputs and export project data after the collaboration?

Evidence and Regulation

FDA Clearances on Record

No clearance is linked in this directory. That is not automatically a mark against the company. Some products support the people doing the work instead of reading a patient image or signal themselves.

First-Hand Sources